Modality
Fusion Protein
MOA
AuroraAi
Target
TIGIT
Pathway
Cell Cycle
HS
Development Pipeline
Preclinical
May 2023
→ Sep 2026
PreclinicalCurrent
NCT03688214
1,611 pts·HS
2023-05→2026-09·Not yet recruiting
1,611 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-193w awayOrphan Drug· HS
2026-09-196mo awayInterim· HS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
Preclinical
Not yet…
Catalysts
Orphan Drug
2026-04-19 · 3w away
HS
Interim
2026-09-19 · 6mo away
HS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03688214 | Preclinical | HS | Not yet recr... | 1611 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-8757 | Alnylam | Preclinical | TIGIT |